Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Hepatitis C Virus Envelope Protein E2 - Overview Hepatitis C Virus Envelope Protein E2 - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development Aviragen Therapeutics Inc Ennaid Therapeutics LLC Integrated BioTherapeutics Inc Toray Industries Inc Hepatitis C Virus Envelope Protein E2 - Drug Profiles CIGB-230 - Drug Profile Product Description Mechanism Of Action R&D Progress E-137 - Drug Profile Product Description Mechanism Of Action R&D Progress E-20 - Drug Profile Product Description Mechanism Of Action R&D Progress hepatitis C (strain H77) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress hepatitis C (virus-like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress hepatitis C vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress hepatitis C vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit E2 for Hepatitis C - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV - Drug Profile Product Description Mechanism Of Action R&D Progress teslexivir - Drug Profile Product Description Mechanism Of Action R&D Progress Hepatitis C Virus Envelope Protein E2 - Dormant Products Hepatitis C Virus Envelope Protein E2 - Discontinued Products Hepatitis C Virus Envelope Protein E2 - Product Development Milestones Featured News & Press Releases Nov 29, 2017: Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma Feb 08, 2016: Biota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma Oct 31, 2013: Results of Anaconda Pharma's Phase IIa study released Jun 10, 2013: IBT and Stanford Awarded STTR Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Aviragen Therapeutics Inc, H1 2018 Pipeline by Ennaid Therapeutics LLC, H1 2018 Pipeline by Integrated BioTherapeutics Inc, H1 2018 Pipeline by Toray Industries Inc, H1 2018 Dormant Projects, H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Aviragen Therapeutics Inc Ennaid Therapeutics LLC Integrated BioTherapeutics Inc Toray Industries Inc